Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
595.2(c) 599.2(c) 607.4(c) 600(c) 589.4 Last
165 053 192 630 246 639 224 816 8 494 Volume
+0.30% +0.67% +1.37% -1.22% -1.77% Change
More quotes
Financials
Sales 2020 6 161 M 6 944 M 6 944 M
Net income 2020 844 M 952 M 952 M
Net Debt 2020 2 915 M 3 285 M 3 285 M
P/E ratio 2020 51,9x
Yield 2020 0,49%
Sales 2021 6 546 M 7 378 M 7 378 M
Net income 2021 969 M 1 092 M 1 092 M
Net Debt 2021 2 448 M 2 759 M 2 759 M
P/E ratio 2021 45,1x
Yield 2021 0,53%
Capitalization 44 573 M 50 227 M 50 239 M
EV / Sales 2020 7,71x
EV / Sales 2021 7,18x
Nbr of Employees 15 913
Free-Float 99,6%
More Financials
Company
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for... 
More about the company
Notations Surperformance© of Lonza Group AG
Trading Rating : Investor Rating :
More Ratings
All news about LONZA GROUP AG
01:53aLONZA : Books Higher 2020 Earnings; Increases Dividend
DJ
01:22aLONZA : FY20 Profit Rises On Positive Pharma Biotech, Nutrition Performance
MT
01:06aLONZA : Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Bi..
PU
01/25Lonza Partner Moderna's COVID-19 Shot Proves Effective Against New Variants
MT
01/24MARKET CHATTER : Lonza's $4 Billion Specialty Ingredients Business Attracts Bid ..
MT
01/20LONZA : NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosa..
AQ
01/19LONZA : Aruvant chooses Lonza to Manufacture ARU-1801 a Potentially curative Tre..
AQ
01/19LONZA : Signs Agreement to Sell Two Sites to NextPharma
DJ
01/19LONZA : to Divest Two Lipid Oral Dosage Producing Sites in France, UK, to NextPh..
MT
01/18LONZA : to Manufacture Sickle Cell Disease Therapy for Aruvant Sciences
MT
01/18LONZA : Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Tr..
PU
01/17LONZA : Partner Moderna to Deliver 7.5 Million COVID-19 Shots to Switzerland By ..
MT
01/15GLOBAL MARKETS LIVE: Citigroup, Wells Fargo, SAP…
01/15LONZA : Invitation to Lonza's Full-Year Results 2020 Conference Call and Webcast
PU
01/14Lonza Group Awaits Swiss Regulator Licensing For Moderna Vaccine Ingredients
MT
More news
News in other languages on LONZA GROUP AG
03:05aFMI, Super-cycle et Microsoft au programme
02:38aLonza steigert Gewinn und treibt Verkauf des Chemiegeschäfts voran
02:27aEN DIRECT DES MARCHES : LVMH, Microsoft, Sartorius, Somfy, Solutions 30, Sanofi,..
02:14aSTOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
02:08aLonza a soigné croissance et rentabilité en 2020
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Stock Trading Strategies
LONZA GROUP AG - 2020
The stock is approaching a major resistance level
BUY
More Stock Trading Analysis
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 610,79 CHF
Last Close Price 600,00 CHF
Spread / Highest target 28,9%
Spread / Average Target 1,80%
Spread / Lowest Target -31,7%
EPS Revisions
Managers and Directors
NameTitle
Pierre-Alain Ruffieux Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG5.49%50 227
MODERNA, INC.45.35%60 120
CELLTRION, INC.-10.58%39 891
IQVIA HOLDINGS INC.0.65%34 576
SEAGEN INC.-1.43%31 230
HANGZHOU TIGERMED CONSULTING CO.,LTD18.50%23 591